Ironwood Pharmaceuticals Inc expected to post earnings of 21 cents a share - Earnings Preview

Ironwood Pharmaceuticals

13/02/2024 14:23

* Ironwood Pharmaceuticals Inc  IRWD.OQ   IRWD.O  is
expected
to show a rise in quarterly revenue when it reports  results on
February 15 for the period ending December 31 2023
    * The Boston Massachusetts-based  company is expected to
report a
9.6% increase in revenue to $117.484 million from $107.2 million
a year ago, according to the mean estimate from 6 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Ironwood Pharmaceuticals
Inc
is for earnings of 21 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Ironwood
Pharmaceuticals Inc is $20.50​, above​ its last closing price
of $15.37. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  0.17        0.16       0.09      Missed  -42.9
 Jun. 30 2023  0.26        0.25       0.31      Beat    25.7
 Mar. 31 2023  0.23        0.24       0.25      Beat    3.1​
 Dec. 31 2022  0.26        0.27       0.27      Met     0
 ​​Sep.        0.26        0.27       0.28      Beat    5.7
 30 2022                                                
 Jun. 30 2022  0.30        0.30       0.21      Missed  -28.8​
 Mar. 31 2022  0.25        0.26       0.21      Missed  -17.6
 Dec. 31 2021  0.36        0.35       0.27      Missed  -23.6
 This summary was machine generated February 13 at 14:23 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)